Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF4, IBI-101(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8750MR)

This product GTTS-WQ8750MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF4 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_003327.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7293
UniProt ID P43489
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF4, IBI-101(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8750MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ13934MR IVTScrip™ mRNA-Anti-PDCD1, REGN-2810(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-2810
GTTS-WQ15233MR IVTScrip™ mRNA-Anti-CD38, TAK-079(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA TAK-079
GTTS-WQ12275MR IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MSB-0010718C
GTTS-WQ1654MR IVTScrip™ mRNA-Anti-GP6, ACT-017(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ACT-017
GTTS-WQ5658MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CDX-011
GTTS-WQ7590MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA G-CSF
GTTS-WQ139MR IVTScrip™ mRNA-Anti-CA9, 124I_WX-G250(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 124I_WX-G250
GTTS-WQ6077MR IVTScrip™ mRNA-Anti-CCL2, CNTO 888(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CNTO 888
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW